Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-08
2008-01-08
Chang, Celia (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S011000, C546S223000, C546S232000, C534S010000, C534S751000
Reexamination Certificate
active
07317103
ABSTRACT:
Generally, the present invention is directed to central nervous system dopamine transporter-imaging agents and methods of use thereof. In certain embodiments, the present invention relates to radiolabeled piperidine derivatives for use as imaging agents in the diagnosis of Parkinson's disease. Another aspect of the present invention relates to piperidine monoamine transporter ligands, comprising a functional group capable of chelating a radionuclide, e.g., technetium, and methods of use thereof.
REFERENCES:
patent: 5136038 (1992-08-01), Bodor
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5359115 (1994-10-01), Campbell et al.
patent: 5362899 (1994-11-01), Campbell
patent: 5440016 (1995-08-01), Blondelle et al.
patent: 5480971 (1996-01-01), Houghten et al.
patent: 5919934 (1999-07-01), John et al.
patent: 6171576 (2001-01-01), Meltzer et al.
patent: 0 200 211 (1986-11-01), None
patent: WO 91/07087 (1991-05-01), None
patent: WO 92/10092 (1992-06-01), None
patent: WO 93/09668 (1993-05-01), None
patent: WO 93/20242 (1993-10-01), None
patent: WO 94/08051 (1994-04-01), None
patent: WO 98/37055 (1998-08-01), None
patent: WO 01/83436 (2001-11-01), None
patent: WO 01/98266 (2001-12-01), None
Hoepping et al. “Synthesis and biological . . . ” CA 132:119356 (1999).
Cutler et al. “Labeling and in vivo evaluation of . . . ” Nuclear medicine $ Biol. v.27 (2000)p. 375-380.
Sohn Y S “Coordination modes of sulfur containing . . . ” CAS 1995:921246 abstract (1995).
Kung et al. “[99mTc]trodat-a:a novel . . . ” Eur. J. Nuclear Med. v.24, (1997) p. 372-380.
Meegalla et al. “First example or . . . ” CA 124:899332 (1995).
Rey et al. “Oxorhenium . . . ” J. Labelled Cpd. Radiopharm. v. 43, p. 347-358 (2000).
Innis et al.; “Single Photon Emission Computed Tomography Imaging of Monoamine Reuptake Sites in Primate Brain With [123I] CIT”, European Journal of Pharmacology 200, 369-370, (1991).
Kung et al.; “Imagine of Dopamine Transporters in Humans with Technetium-99m TRODAT-1”, European Journal of Nuclear Medicine, 23(11):1527-1530, (1996).
Dahl et al.; “Deletion Mapping of X-Linked Mixed Deafness (DFN3) Identifies A 265-525-kb Region Centrometric of DXS26”, Am. J. Hum. Genet. 56: 999-1002, (1995).
Valerio et al.; “Synthesis of Peptide analogues Using the Multiplin Peptide Synthesis Method”, Analytical Biochemistry 197:168-177 (1991).
Stoof et al.; “Leads for the Development of Neuroprotective Treatment in Parkinson's Disease and Brain Imaging Methods for Estimating Treatment Efficacy”, European Journal of Pharmacology 375: 75-86, (1999).
Gallop et al.; “Application of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries”, Journal of Medicinal Chemistry, 37(9) : 1233-1251, (Apr. 29, 1994).
Berge et al.; “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 66(1): 1-19, (Jan. 1977).
Ohlmeyer et al.; “Complex Synthetic Chemical Libraries Indexed with Molecular Togs”, Proc. Natl. Acad. Sci., USA, 90: 10922-10926, (Dec. 1993).
Innis et al.; “Single Photon Emission Computed Tomographic Imaging Demonstrates Loss of Striatal Dopamine Transporeters in Parkinson Disease”, Proc. Natl. Acad. Sci. , USA 90: 11965-11969, (Dec. 1993).
Kung et al.; “Synthesis of New Bis (Aminoethanethiol) (BAT) Derivatives: Possible Ligands for99mTc Brain Imaging Agents”, J. Med. Chem. 28: 1280-1284, (1985).
Meltzer et al.; “Substituted 3-Phenyltropane Analogs of Cocaine: Synthesis, Inhibition of Binding at Cocaine Recognition Sites, and Positron Emission Tomography Imaging”, J.Med. Chem. 36: 855-862, ( 1993).
Carroll et al.; “Cocaine Receptor: Biochemical Characterization and Structure-Activity Relationships of Cocaine Analogues at the Dopamine Transporter”, Journal of Medical Chemistry, 35(6): 969-981, (Mar. 20, 1992).
Meegalla et al.; “First Example of a99mTc Complex as a Dopamine Transporter Imaging Agent”, J. Am. Chem. Soc. 117: 11037-11038, (1995).
Smith et al.; “Turning Selectivity of Monoamine Transporter Inhibitors by the Stereochemistry of the Nitrogen Lone Pair”, J. Am. Chem. Soc. 120: 9072-9073, Sep. 1998).
Neumeyer et al.; “[123]-2β-Carbometholxy-3β-(-(4-iodophenyl) Tropane: High-Affinity SPECT Radiotracer of Monoamine Reuptake Sites in Brain”, J. Med. Chem. 34 : 3144-3146, (1991).
Hoepping et al.; “Synthesis and Biological Evaluation of Two Novel Dat-Binding Technetium Complexes Containing a Piperidine Based Analogue of Cocaine”, Bioorganic & Medicinal Chemistry Letters, 9: 3211-3216, (1999).
Gu et al.; “Stable Expression of Biogenic Amine Transporters Reveals Differences in Inhibitor Sensitivity, Kinetics, and Ion Dependence”, The Journal of Biological Chemistry, 269 (10): 7124-7130, (1994).
Frost et al.; “Positron Emission Tomographic Imaging of the Dopamine Transporter withIIC-WIN 35,428 Reveals Marked Declines in Mild Parkinson's Disease”, Annals of Neurology, 34: 423-431, (1993).
Blaney and Dixon, “Receptor Modeling by Distance Geometry”, Annual Reports in Medicinal Chemistry, 26:281-286, (1991).
Meegalla et al.; “Synthesis and Characterization of Technetium-99m- Labeled Tropanes as Dopamine Transporter-Imaging Agent”, J. Med. Chem. 40: 9-17, (1997).
Hamilton and Steiner, “Immunophilins: Beyond Immunosuppression”, Journal of Medicinal Chemistry, 41(26):5119-5143, (Dec. 17, 1998).
Luyt et al.; “An N2S2Bifunctional Chelator for Technetium-99m and Rhenium: Complexation, Conjugation, and Epimerization to a Single Isomer”, Bioconjugate Chem. 10: 470-479, (1999).
Hom and katzenellenbogen; “Technetium-99m-Labeled Receptor-Specific Small-Molecule Radiopharmaceuticals: Recent Developments and Encouraging Results”, Nuclear Medicine and Biology, 24: 485-498, (1997).
Nicholson et al.; “The Synthesis and Characterization of [MCI3(N═NC5H4NH) (HN═NC5H4N)] From [MO4] (where M═Re, Tc) Organodiazenido, Organodiazene-Chelate Complexes. The X-ray Structure of [ReC13(N═NC5H4NH) (HN═NC5H4N )]”, Inorganica Chimica Acta, 252: 421-426, (1996).
Rose et al.; “Synthesis and Characterization of Organohydrazino Complexes of Technetium, Rhenium, and Molybdenum with the {M(η1—HxNNR)(η2-HyNNR)} Core and Their Relationship to Radiolabeled Organohydrazine-Derivatized Chemotactic Peptides With Diagnostic Applications”, Inorg. Chem. 37: 2701-2716, (1998).
Fowler et al.; “Mapping Cocaine Binding Sites in Human and Baboon Brain In Vivo”, Synapse, 4:371-377, (1989).
Villemagne et al.; “Doses of GBR12909 That Suppress Cocaine Self-Administration in Non-Human Primates Substantially Occupy Dopamine Transporters as Measured by [ 11 C ] WIN35,428 PET Scans”, Synapse 32: 44-50, (1999).
Shaya et al.; “In Vivo Imaging of Dopamine Reuptake Sites in the Primate Brain Using Single Photon Emission Computed Tomography (SPECT) and Iodine-123 Labeled RTI-55”, Synapse 10: 169-172 (1992).
Ilgin et al.; “PET Imaging of Dopamine Transporter in Progressive Supranuclear Palsy and Parkinson's Disease”, Neurology 52: 1221-1226, (1999).
Kaufman and Madras; “Distribution of Cocaine Recognition Sites in Monkey Brain: II. EX Vivo Autoradiography With [3H] CFT and [1231] RTI-55”, Synapse 12: 99-111, (1992).
Jacobs and Fodor, “Combinatorial Chemistry- Applications of Light-directed Chemical Synthesis”, TIBTECH. 12:19-26, (Jan. 1994).
Chen et al.; ““Analogous” Organic Synthesis of Small Compound Libraries: Validation of Combinatorial Chemistry in Small-Molecule Synthesis”, J. Am. Chem. Soc. 116: 2661-2662, (1994).
Kerr et al.; “Encoded Combinatorial Peptide Libraries Containing Non-
Babich John W.
Smith Miles P.
Chang Celia
Ewing James F.
Foley & Lardner LLP
Molecular Insight Pharmaceuticals, Inc.
Morency Michel
LandOfFree
Imaging agents for diagnosis of Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imaging agents for diagnosis of Parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imaging agents for diagnosis of Parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747379